Targeting the CSF1/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy

Qian Wang, Jian‐Hong Wang, Ke Xu, Zhi‐Bin LuoFrontiers in Immunology 2024 · DOI

Abstract

Pancreatic cancer (PC) is a highly aggressive and lethal malignancy characterized by a complex tumor microenvironment (TME) and immunosuppressive features that limit the efficacy of existing treatments. This paper reviews the potential of combining ultrasound with macrophage exhaustion in the treatment of pancreatic cancer. Macrophages, particularly tumor-associated macrophages (TAMs), are crucial in pancreatic cancer progression and immune escape. Prolonged exposure to the immunosuppressive TME leads to macrophage exhaustion, reducing their anti-tumor ability and instead promoting tumor growth. The CSF1/CSF1R signaling pathway is key in macrophage recruitment and functional regulation, making it an effective target for combating macrophage exhaustion. Ultrasound technology not only plays a significant role in diagnosis and staging but also enhances therapeutic efficacy by guiding radiofrequency ablation (RFA) and percutaneous alcohol injection (PEI) in combination with immunomodulators. Additionally, ultrasound imaging can monitor the number and functional status of TAMs in real-time, providing a basis for optimizing treatment strategies. Future studies should further investigate the combined use of ultrasound and immunomodulators to refine treatment regimens, address challenges such as individual variability and long-term effects, and offer new hope for pancreatic cancer patients.

Introduction

Pancreatic cancer (PC) remains one of the most challenging malignancies in oncology, with a five-year survival rate of approximately 13%. Most patients are diagnosed at advanced stages, where traditional therapies like chemotherapy often fail due to rapid resistance. A primary driver of this resistance is the complex and immunosuppressive Tumor Microenvironment (TME), which acts as an "immunological shield" protecting the tumor from the host's immune system.

The Role of Tumor-Associated Macrophages (TAMs)

Central to the TME are Tumor-Associated Macrophages (TAMs). While macrophages are typically the body's first line of defense, the PC TME "exhausts" them, shifting their functional state. Instead of attacking the cancer (M1 phenotype), they are reprogrammed into a pro-tumor state (M2 phenotype). These M2-like TAMs actively promote tumor growth, angiogenesis, and metastasis while suppressing the activity of effector T-cells.

Overview of Pancreatic Cancer TME, TAM modulation, Ultrasound role, and CSF1/CSF1R signaling.

The CSF1/CSF1R Signaling Axis

The Colony-Stimulating Factor 1 (CSF1) and its receptor (CSF1R) are the primary regulators of macrophage recruitment, differentiation, and survival. In pancreatic cancer, the overexpression of CSF1 creates a recruitment pipeline for monocytes, which then differentiate into immunosuppressive TAMs within the tumor. Targeting this pathway offers a highly specific means to either deplete these pro-tumor cells or "repolarize" them back into anti-tumor fighters.

Therapeutic Pillars: Molecular Targeting and Ultrasound

The proposed synergistic approach rests on two main pillars:

  1. Molecular Targeting: Strategies include the use of small molecule inhibitors and monoclonal antibodies. Small molecule inhibitors block the intracellular signaling of CSF1R, while monoclonal antibodies target the receptor's extracellular domain to induce its degradation.
  2. Advanced Ultrasound Applications: Ultrasound (US) has evolved from a diagnostic tool into a therapeutic one. Techniques like Radiofrequency Ablation (RFA) and Percutaneous Alcohol Injection (PEI) can physically disrupt the tumor. This disruption not only reduces tumor mass but also releases tumor-associated antigens, potentially "heating up" the cold TME and priming the immune system for a more robust response.

Clinical Landscape

Several agents targeting the CSF1/CSF1R pathway are currently in various stages of clinical trials. These agents are often tested in combination with other immunotherapies to overcome the inherent resistance of pancreatic tumors.

Summary of clinical-stage CSF1R-targeted small molecule inhibitors and monoclonal antibodies.

Clinical data suggests that while monotherapy may have limited impact, combining CSF1R inhibitors with checkpoint inhibitors (such as anti-PD-1/PD-L1) shows significant promise. By removing the macrophage-mediated "brakes," these combinations can restore the efficacy of T-cell-mediated anti-tumor responses.

Limitations and Future Directions

Despite the potential of this combined strategy, several challenges remain. The TME is highly heterogeneous, meaning treatment responses can vary significantly between patients. Furthermore, the long-term systemic impact of depleting macrophages—which have essential roles in normal tissue repair—is not yet fully understood. Future research is focused on developing bispecific antibodies and utilizing nanotechnology for ultrasound-triggered, site-specific drug release to maximize therapeutic precision.

Conclusion

The integration of ultrasound-guided physical interventions with molecular targeting of the CSF1/CSF1R pathway represents a transformative strategy for pancreatic cancer therapy. By dismantling the immunosuppressive shield of the TME, this synergistic approach offers a new path toward improving survival and quality of life for patients facing this devastating disease.

Summary updated

Abstract

Pancreatic cancer (PC) is a highly aggressive and lethal malignancy characterized by a complex tumor microenvironment (TME) and immunosuppressive features that limit the efficacy of existing treatments. This paper reviews the potential of combining ultrasound with macrophage exhaustion in the treatment of pancreatic cancer. Macrophages, particularly tumor-associated macrophages (TAMs), are crucial in pancreatic cancer progression and immune escape. Prolonged exposure to the immunosuppressive TME leads to macrophage exhaustion, reducing their anti-tumor ability and instead promoting tumor growth. The CSF1/CSF1R signaling pathway is key in macrophage recruitment and functional regulation, making it an effective target for combating macrophage exhaustion. Ultrasound technology not only plays a significant role in diagnosis and staging but also enhances therapeutic efficacy by guiding radiofrequency ablation (RFA) and percutaneous alcohol injection (PEI) in combination with immunomodulators. Additionally, ultrasound imaging can monitor the number and functional status of TAMs in real-time, providing a basis for optimizing treatment strategies. Future studies should further investigate the combined use of ultrasound and immunomodulators to refine treatment regimens, address challenges such as individual variability and long-term effects, and offer new hope for pancreatic cancer patients.
BibTeX
@inproceedings{wang2024targeting,
  author = {Qian Wang and Jian‐Hong Wang and Ke Xu and Zhi‐Bin Luo},
  title = {{Targeting the CSF1/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1481247},
}
Figure